Industry Press Releases

Juniper Pharmaceuticals Reschedules Annual General Meeting

Wednesday, Apr 29, 2015
Pressreleases

Juniper Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in women's health, has rescheduled its 2015 Annual General Meeting of Shareholders from June 2, 2015 to July 7, 2015. The Company has previously announced that it has initiated a search for a new Board Director to replace retiring Chairman Stephen Kasnet.  The postponement will provide the Board of Directors additional time to continue to identify, recruit and evaluate qualified candidates to serve on the Board. The Company will announce the time and location of the meeting at a later date.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) (formerly Columbia Laboratories) is a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in women's health. Juniper has a successful heritage in developing pharmaceutical products, including CRINONE® 8% (progesterone gel), which is marketed by Actavis, Inc. in the U.S. and by Merck Serono S.A. in over 60 countries worldwide. The Company is uniquely positioned to leverage in-house pharmaceutical development, clinical trial manufacturing, and analytical capabilities to advance an internal development pipeline, while also providing valuable consultative services to its pharmaceutical industry customers. Please visit www.juniperpharma.com for more information.

Juniper Pharmaceuticals™ and Juniper Pharma Services™ are trademarks of Juniper Pharmaceuticals, Inc., in the U.S. and EU.

CRINONE® is a registered trademark of Actavis, Inc. in the U.S.

Contact
Katja Buhrer
MBS Value Partners
(212) 661-7004
katja.buhrer@mbsvalue.com

 

prnewswire.com

Other Press Releases